Havrdova, E <br/><br/>
Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies.  [electronic resource] 

 -  European journal of neurology  May 2017 
 - 726-733 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1468-1331 
<br/><br/><label>Standard No.: </label>10.1111/ene.13272  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Delayed-Action Preparations<br/>Dimethyl Fumarate--administration & dosage<br/>Disease Progression<br/>Female<br/>Glatiramer Acetate--administration & dosage<br/>Humans<br/>Immunosuppressive Agents--administration & dosage<br/>Magnetic Resonance Imaging--methods<br/>Male<br/>Middle Aged<br/>Multiple Sclerosis, Relapsing-Remitting--diagnostic imaging<br/>Recurrence<br/>Treatment Outcome